AstraZeneca "incredibly excited" by lung cancer treatment trial
.jpg)
Independent Data Monitoring Committee (IDMC) recommends unblind Phase III trial of Tagrisso 2 years ahead of schedule.
AstraZeneca has cause for celebration after the Phase III trial for Tagrisso (osimertinib) in the adjuvant treatment of postsurgery patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) will be unblinded early following a recommendation from an IDMC based on its determination of overwhelming efficacy.
In a Phase III trial named ADAURA, Tagrisso was pitted against placebo for a treatment duration of up to 3 years, during which investigators measured disease-free survival (DFS).
José Baselga, AstraZeneca's Executive Vice President, Oncology R&D said they were "incredibly excited with the unprecedented results" in patients with early-stage EGFRm NSCLC.
The trial will continue to assess the secondary endpoint of overall survival.
In its communication to AstraZeneca, the IDMC did not raise any new safety concerns.
José Baselga said: "We are thrilled by the recommendation to unblind the Phase III ADAURA trial much earlier than expected. Lung cancer is a devastating diagnosis and for the first time an EGFR-targeted medicine can now provide the hope of cure."
The company has said it will present the data at a forthcoming medical meeting.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.